-1.04%
0.32%
-2.67%
1.50%
12.74%
26.27%
26.27%
AI Spotlight on HLN
Company Description
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum.
The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022.Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Market Data
| Last Price | 9.47 |
| Change Percentage | -1.04% |
| Open | 9.37 |
| Previous Close | 9.57 |
| Market Cap ( Millions) | 42868 |
| Volume | 15365694 |
| Year High | 10.8 |
| Year Low | 7.89 |
| M A 50 | 9.54 |
| M A 200 | 9.34 |
Financial Ratios
| FCF Yield | 0.00% |
| Dividend Yield | 0.02% |
| ROE | 6.54% |
| Debt / Equity | 53.36% |
| Net Debt / EBIDTA | 395.44% |
| Price To Book | 2.07 |
| Price Earnings Ratio | 31.61 |
| Price To FCF | 0 |
| Price To sales | 3.01 |
| EV / EBITDA | 20.06 |
News
- Jan -29 - Haleon to invest $54 mln in US R&D centre to boost product innovation
- Jan -28 - AHCO vs. HLN: Which Stock Is the Better Value Option?
- Jan -15 - Pfizer to further reduce stake in Haleon through share sale
- Jan -15 - Pfizer Sells 700 Million Haleon Shares for $3 Billion
- Jan -14 - Pfizer intends to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner
- Jan -09 - TUMS Teams Up with DraftKings to Launch TUMS Fantasy Foodball Pool, Making Gameday Food Dreams a Reality
- Dec -10 - Haleon: Guidance Implies Uncertainty Around Flu Season
- Dec -02 - Haleon Welcomes Joe Sta-Romana as Chief Customer Officer to Lead US Growth and Transformation
- Nov -18 - Dividend Income: Lanny's October 2024 Summary
- Nov -04 - Haleon Selects Vistar Media as Preferred Global Partner for Programmatic Out-of-Home (OOH) Advertising
- Nov -02 - Haleon plc (HLN) Q3 2024 Sales Call Transcript
- Oct -31 - Panadol maker Haleon takes hit from currency headwinds
- Oct -31 - Haleon reports marginal decline in third-quarter revenue
- Oct -09 - Haleon gets target hike as UBS raises 'forever' sales target
- Oct -07 - Futura Medical in line for $5m milestone payment as Haleon's US Eroxon launch gets underway
- Oct -03 - HLN or PODD: Which Is the Better Value Stock Right Now?
- Oct -01 - Haleon's buy rating restated after Pfizer cuts down stake
- Oct -01 - Haleon buys back some shares as Pfizer sells down stake
- Oct -01 - Pfizer offloads $3.3 bln stake in Sensodyne-maker Haleon
- Sep -30 - Pfizer to offload about 5.9% stake in UK's Haleon, says bookrunner
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Oral Health
Expected Growth : 7.5 %
What the company do ?
Haleon plc's Oral Health segment offers a range of oral care products, including toothpaste, toothbrushes, and mouthwash, under brands like Sensodyne and Corsodyl.
Why we expect these perspectives ?
Haleon plc's Oral Health segment growth of 7.5% is driven by increasing consumer awareness of oral health, rising demand for premium oral care products, and expansion into emerging markets. Additionally, the company's focus on innovation, digital marketing, and strategic partnerships contribute to its growth momentum.
Segment n°2 -> Pain Relief
Expected Growth : 7.8 %
What the company do ?
Pain Relief from Haleon plc provides effective and trusted pain relief medications, including acetaminophen and ibuprofen-based products, to help alleviate headaches, fever, and body aches.
Why we expect these perspectives ?
Haleon plc's 7.8% growth in Pain Relief is driven by increasing demand for over-the-counter (OTC) pain management solutions, rising prevalence of chronic pain conditions, and growing awareness of self-care. Additionally, the company's strong brand portfolio, including Advil and Panadol, and strategic expansion into emerging markets contribute to its growth momentum.
Segment n°3 -> Digestive Health and Other
Expected Growth : 7.2 %
What the company do ?
Haleon plc's Digestive Health and Other segment includes products for gastrointestinal health, pain relief, and other self-care products.
Why we expect these perspectives ?
Haleon's Digestive Health and Other segment's 7.2% growth is driven by increasing consumer awareness of gut health, rising demand for probiotics and prebiotics, and expanding product portfolios in emerging markets. Additionally, the segment benefits from strategic partnerships, innovative product launches, and effective marketing campaigns.
Segment n°4 -> Respiratory Health
Expected Growth : 7.9 %
What the company do ?
Respiratory Health from Haleon plc focuses on providing innovative treatments and self-care solutions for respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD).
Why we expect these perspectives ?
Haleon plc's Respiratory Health segment growth of 7.9% is driven by increasing prevalence of respiratory diseases, growing demand for inhalers and nebulizers, and expansion into emerging markets. Additionally, the company's focus on innovation, strategic partnerships, and cost savings initiatives have contributed to the segment's growth.
Segment n°5 -> Vitamins, Minerals and Supplements
Expected Growth : 8.1 %
What the company do ?
Haleon plc offers a range of vitamins, minerals, and supplements to support overall health and wellness, including Centrum, Caltrate, and Polident.
Why we expect these perspectives ?
Haleon plc's Vitamins, Minerals, and Supplements segment growth of 8.1% is driven by increasing consumer focus on preventative healthcare, rising demand for immunity-boosting products, and expanding e-commerce channels. Additionally, the company's strategic partnerships, innovative product launches, and geographic expansion into emerging markets contribute to the segment's growth.
Haleon Plc Products
| Product Range | What is it ? |
|---|---|
| Pain Relief | Haleon's pain relief products provide fast and effective relief from headaches, backaches, and other types of pain. |
| Vitamins and Supplements | Haleon's vitamins and supplements support overall health and wellness, including immune system support and energy boosting. |
| Cold and Flu | Haleon's cold and flu products provide relief from symptoms such as congestion, cough, and fever. |
| Digestive Health | Haleon's digestive health products support healthy digestion, relieve heartburn and indigestion, and promote regularity. |
| Skin Health | Haleon's skin health products provide relief from skin conditions such as acne, eczema, and psoriasis. |
| Allergy Relief | Haleon's allergy relief products provide relief from seasonal and perennial allergies. |
| Sleep Aids | Haleon's sleep aids promote healthy sleep patterns and provide relief from insomnia and restlessness. |
Haleon plc's Porter Forces
Threat Of Substitutes
Haleon plc's products are moderately susceptible to substitutes, as consumers have some alternatives for pain relief and wellness products.
Bargaining Power Of Customers
Haleon plc's customers have limited bargaining power due to the company's strong brand portfolio and wide distribution network.
Bargaining Power Of Suppliers
Haleon plc's suppliers have moderate bargaining power, as the company relies on a diverse supplier base for raw materials and manufacturing.
Threat Of New Entrants
The threat of new entrants is low for Haleon plc, as the company has a strong brand presence and significant barriers to entry in the pharmaceutical industry.
Intensity Of Rivalry
The intensity of rivalry is high in the pharmaceutical industry, with many established players competing for market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 36.28% |
| Debt Cost | 5.44% |
| Equity Weight | 63.72% |
| Equity Cost | 5.44% |
| WACC | 5.44% |
| Leverage | 56.94% |
Haleon plc : Quality Control
Haleon plc passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IPN.PA | Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors … |
| NOVO-B.CO | Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. … |
| MRK.DE | MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, … |
| FAE.MC | Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter … |
| GSK.L | GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Faes Farma
A-Score
1-Year Total Return ->
🥈
Ipsen
A-Score
1-Year Total Return ->
🥉
GSK
A-Score
1-Year Total Return ->
4
Haleon
A-Score
1-Year Total Return ->
5
Merck KGaA
A-Score
1-Year Total Return ->
6
